Dispensation of a 52-mg LNG IUD, compared to a 19.5-mg LNG IUD, was associated with a significantly increased use of an antidepressant within 2 years
aOR 1.13 (95% CI, 1.05 to 1.21)
The association with antidepressant use persisted in females without a medical history
aOR 1.19 (95% CI, 1.09 to 1.31)
There was no significant difference between the groups in the use of other psychotropic drugs
aOR 1.05 (95% CI 0.99 to 1.12)
aOR 1.09 (95% CI, 0.99 to 1.19)
Individuals <25 years who were using a 52-mg LNG IUD were at higher risk of using hypnotics
aOR 1.61 (95% CI, 1.04 to 2.48)
There were no other significant associations between LNG IUD dose and psychotropic drug use for other age categories
Compared to the 19.5-mg LNG IUD, the 52-mg IUD was associated with a small but significant increase in the risk of new antidepressant use
These differences in antidepressant use by IUD dose are unlikely to be clinically significant on an individual level
The authors state
The lack of a strong dose-response relationship may suggest that levonorgestrel, and thereby serum progestin, does not markedly cause mood disturbances in females using a levonorgestrel intrauterine system
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan